PT - JOURNAL ARTICLE AU - Georgina L Ryland AU - Kate Jones AU - Melody Chin AU - John Markham AU - Elle Aydogan AU - Yamuna Kankanige AU - Marisa Caruso AU - Jerick Guinto AU - Michael Dickinson AU - H Miles Prince AU - Kwee Yong AU - Piers Blombery TI - Novel genomic findings in multiple myeloma identified through routine diagnostic sequencing AID - 10.1136/jclinpath-2018-205195 DP - 2018 May 14 TA - Journal of Clinical Pathology PG - jclinpath-2018-205195 4099 - http://jcp.bmj.com/content/early/2018/05/14/jclinpath-2018-205195.short 4100 - http://jcp.bmj.com/content/early/2018/05/14/jclinpath-2018-205195.full AB - Aims Multiple myeloma is a genomically complex haematological malignancy with many genomic alterations recognised as important in diagnosis, prognosis and therapeutic decision making. Here, we provide a summary of genomic findings identified through routine diagnostic next-generation sequencing at our centre.Methods A cohort of 86 patients with multiple myeloma underwent diagnostic sequencing using a custom hybridisation-based panel targeting 104 genes. Sequence variants, genome-wide copy number changes and structural rearrangements were detected using an inhouse-developed bioinformatics pipeline.Results At least one mutation was found in 69 (80%) patients. Frequently mutated genes included TP53 (36%), KRAS (22.1%), NRAS (15.1%), FAM46C/DIS3 (8.1%) and TET2/FGFR3 (5.8%), including multiple mutations not previously described in myeloma. Importantly we observed TP53 mutations in the absence of a 17 p deletion in 8% of the cohort, highlighting the need for sequencing-based assessment in addition to cytogenetics to identify these high-risk patients. Multiple novel copy number changes and immunoglobulin heavy chain translocations are also discussed.Conclusions Our results demonstrate that many clinically relevant genomic findings remain in multiple myeloma which have not yet been identified through large-scale sequencing efforts, and provide important mechanistic insights into plasma cell pathobiology.